tbuckley/cabot-search huggingface dataset:
Errata
Journal: Diabetes Care (2008)

The authors report that the data analyses were accidently run on a derived dataset rather than raw data, creating errors in Table 1 and Fig. 2. The new data do not alter the conclusions of the original manuscript; however, some of the P values have changed.The authors apologize for the errors and regret any inconvenience that may have been caused.Corrected versions of Fig. 1 and Table 2, as well as revised wording for the RESULTS and CONCLUSIONS sections, appear below.The online version reflects these changes.In the RESULTS section (p.1041) of the main body of the text, the paragraph entitled "Glucose and insulin responses" should contain the following revised text: Peak insulin concentrations and the IAUCs for glucose from 0 to 120 min and insulin from 0 to 120 min and 0 to 180 min were also significantly reduced after both HV-HPMC doses vs. control (all P Ͻ 0.001).The differences between HPMC and control for glucose IAUC from 0 to 180 min did not reach significance (P ϭ 0.172).An exploratory analysis of values at each time point showed that levels were significantly lower than control in the 4-and 8-g HV-HPMC conditions from 15 through 60 min for glucose and from 15 through 90 min for insulin.In the fifth paragraph of the CONCLUSIONS section (p.1042) of the main body of the text, the first sentence should appear as follows: Inclusion of HV-HPMC reduced the mean IAUCs from 0 to 120 min for glucose by ϳ30% and for insulin by 39 -46%, thus effectively lowering dietary "glycemic load" (22).
Abstract P124: Network Meta-analysis of the Effects of Breast Cancer Hormone Therapy on Changes in Lipid Profiles
Authors: Hsin-Hui Huang, Emma Barinas-Mitchell, Brenda Diergaarde, Chung-Chou Chang, Marnie Bertolet
Journal: Circulation (2017)

Introduction: Adjuvant hormone therapy prolongs survival of patients with early-stage hormone receptor-positive breast cancer (BC). For postmenopausal patients, aromatase inhibitors (AIs) have been shown to improve disease free survival compared to tamoxifen, but the impact on overall survival has been inconsistent. A meta-analysis showed higher risk of cardiovascular diseases (CVDs) for patients taking AIs. Deteriorating lipids induced by AIs may contribute to this result. This analysis aims to compare the effects of hormone therapeutic options on changes in lipids from published randomized clinical trials (RCTs). Methods: RCTs evaluating effects of adjuvant hormone therapy on lipids (total cholesterol, high-density lipoprotein cholesterol (HDLc), low density lipoprotein cholesterol (LDLc), and/or triglycerides) in postmenopausal early-stage BC patients published in PubMed and Embase, prior to Jan. 31, 2016 were reviewed. Bayesian network meta-analysis was used to compare effects of placebo, selective estrogen receptor modulators (SERMs- tamoxifen and toremifene) and AIs (letrozole, anastrozole, and exemstane) on lipids across longitudinal time points. Heterogeneity was examined by meta-regressions adjusting for mean age, baseline lipid value, and prior tamoxifen use. An arm-based random effect model tested the consistency of the direct and indirect evidence of the drug effects. Results: We identified 17 articles from 13 RCTs for a total of 1,913 subjects. The Table summarizes the results, with statistically significant results bolded. Toremifene significantly improved all lipids and was the best choice regardless of covariate adjustment, while tamoxifen had weaker but significant LDLc lowering but opposite HDLc/triglyceride effects to toremifene. AIs generally had little effect on lipids. Conclusions: In general, AIs tend to have worse effects on lipids than SERMs, while only toremifene had beneficial effects on all lipid values. Patients on AIs with high risk of CVD should monitor their lipids.
Adolph Fick (1829-1901), mathematician, physicist, physiologist
Journal: JAMA (1967)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
KANSAS CITY LETTER.
Authors: None S.
Journal: JAMA (1891)

Vaginal Hysterectomy for Carcinoma—Insanity Following Rectal Operation—Methyl-violet for Cancerous Growths—A New College Organized—College Notes. The meetings of the Academy of Medicine have of late been unusually interesting. At the last, Dr. J. F. Binnie, Professor of Pathology in the University, discussed the subject of <h3>VAGINAL HYSTERECTOMY FOR CARCINOMA.</h3> He first presented the history of a case successfully operated upon by himself seven months ago, exhibiting the specimen as well as slides showing the cancerous character of the disease, and then gave a table of 1,169 cases gathered from published reports and from private communication of hitherto unpublished operations; these figures gave a mortality of<i>less than twelve per centum</i>, the total number of deaths being only 137—in view of which it takes a bold man to say the operation is unjustifiable because of immediate danger. And the ultimate results are no less satisfactory—in fact they are rather surprising inasmuch as
A Research Ethics Framework for the Clinical Translation of Healthcare Machine Learning
Authors: Melissa D McCradden, James A Anderson, Elizabeth A. Stephenson, Erik Drysdale, Lauren Erdman, Anna Goldenberg, Randi Zlotnik Shaul
Journal: The American Journal of Bioethics (2022)

The application of artificial intelligence and machine learning (ML) technologies in healthcare have immense potential to improve the care of patients. While there are some emerging practices surrounding responsible ML as well as regulatory frameworks, the traditional role of research ethics oversight has been relatively unexplored regarding its relevance for clinical ML. In this paper, we provide a comprehensive research ethics framework that can apply to the systematic inquiry of ML research across its development cycle. The pathway consists of three stages: (1) exploratory, hypothesis-generating data access; (2) silent period evaluation; (3) prospective clinical evaluation. We connect each stage to its literature and ethical justification and suggest adaptations to traditional paradigms to suit ML while maintaining ethical rigor and the protection of individuals. This pathway can accommodate a multitude of research designs from observational to controlled trials, and the stages can apply individually to a variety of ML applications.
Queries and Minor Notes
Journal: JAMA (1910)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
The relationship between on-treatment lipid levels and clinical outcome: The pravastatin pooling project I. Ford, T. Craven, C. Furberg, R. Byington, A. Tonkin, J. Simes, F. Sacks, E. Braunwald. University of Glasgow, Glasgow, United Kingdom, Wake Forest University, Winston-Salem, NC
Journal: Journal of the American College of Cardiology (2001)
Distinct populations of highly potent TAU seed conformers in rapidly progressing Alzheimer’s disease
Authors: Chae Kim, Tracy Haldiman, Sang-Gyun Kang, Lenka Hromadkova, Zhuang Zhuang Han, Wei Chen, Frances Lissemore, Alan Lerner, Rohan de Silva, Mark L. Cohen, David Westaway, Jiri G. Safar
Journal: Science Translational Medicine (2022)

Rapid replication in vitro implicates distinct populations of misfolded hippocampal 4R TAU protein in accelerated progression of Alzheimer’s disease.
Omicron neutralising antibodies after COVID-19 vaccination in haemodialysis patients
Authors: Edward J Carr, Mary Wu, Ruth Harvey, Roseanne E Billany, Emma C Wall, Gavin Kelly, Michael Howell, George Kassiotis, Charles Swanton, Sonia Gandhi, David LV Bauer, Matthew PM Graham-Brown, Rachel B Jones, Rona M Smith, Stephen McAdoo, Michelle Willicombe, Rupert Beale
Journal: The Lancet (2022)
APPENDICITIS--AND QUICKNESS
Authors: G. W. Thomas
Journal: BMJ (1912)

APPENDICITIS-AND QUICKNESS.SIR,-I would ask Mr. Morton to remember that when I said in a previous communication I liad no fault to find with operation within twelve hours of the onset of an attack of acute appendicitis, it was the question of mortality that was being discussed.On that point there are no grounds for asserting that lharm is done.Tlhis, lhowever, does not prove that suclh a course of action is necessary, and it is because I think it is not so tllat
Phase 2 trial of newly diagnosed high-grade glioma treated with concurrent radiation therapy, temozolomide, and BMX-001.
Authors: Katherine B. Peters, John L. Villano, Nicholas A. Butowski, Adam Louis Cohen, Joe Sammy Mendez, Pierre Giglio, Chi Zhang, Shahzad Raza, Tresa McGranahan, Mina Lobbous, David MacLeod, Shayne Gad, Sara Penchev, David Silberstein, James Crapo
Journal: Journal of Clinical Oncology (2021)

TPS2069 Background: High-grade gliomas (WHO grade III-IV) patients experience marked morbidity and mortality. While the standard of care for newly diagnosed high-grade glioma patients is surgery followed by concurrent chemotherapy and radiation therapy (RT), the outcomes remain poor. BMX-001 (MnTnBuOE-2-PyP 5+ ) is a metalloporphyrin with differential action in response to radiation therapy and chemotherapy-induced oxidative stress. As shown in preclinical evaluations, BMX-001, when used with radiation, can protect normal, healthy tissues and augment cell kill in malignant cancer cells, notably, human glioblastoma xenografts. We evaluated the safety of BMX-001 in combination with concurrent RT and temozolomide (TMZ) in a phase 1 study of newly diagnosed high-grade glioma patients and we found that BMX-001 is safe and well-tolerated in this population. The maximum tolerated dose of BMX-001 during concurrent RT and TMZ was determined to be 28 mg delivered subcutaneously (SC) followed by 16 biweekly SC doses at 14 mg (Peters et al., Neuro-Oncology 2018). Methods: For this multi-site, open-label, phase 2 study (NCT02655601), we will randomize approximately 160 patients 1:1 to concurrent RT and TMZ with BMX-001 versus concurrent RT and TMZ alone. Key eligibility criteria include newly diagnosed histologically confirmed high-grade glioma (WHO III-IV), 18 ≥ years, and Karnofsky performance status ≥ 70%. The primary endpoint is overall survival. Secondary endpoints are objective cognitive performance, bone marrow protection, safety and tolerability, progression-free survival, overall tumor response rate, and plasma pharmacokinetics. Exploratory endpoints are patient-reported outcomes of health-related quality of life (as assessed by Functional Assessment of Cancer Therapy–Brain, Functional Assessment of Cancer Therapy-Cognition, and Functional Assessment of Chronic Illness Therapy-Fatigue), qualitative hair loss, and white matter integrity (as measured by MRI diffusion tensor/susceptibility imaging). Since November 2018, this phase 2 study has enrolled 147 of 160 high-grade glioma patients at nine sites in US. Clinical trial information: NCT02655601.
ACUTE AND LONG-TERM OUTCOMES OF CORONARY STENTING IN WOMEN VERSUS MEN: RESULTS FROM THE NATIONAL CARDIOVASCULAR DATA REGISTRY (NCDR)&amp;reg; CENTERS FOR MEDICARE &amp;amp; MEDICAID SERVICES (CMS)&amp;reg; COHORT
Authors: Monique Anderson, Eric Peterson, J. Matthew Brennan, Dadi (David) Dai, Kevin Anstrom, Sunil Rao, Robert Piana, Andra Popescu, Art Sedrakyan, John Messenger, Pamela Douglas
Journal: Journal of the American College of Cardiology (2012)
Just Words
Authors: Alexander Gode
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Routine neonatal screening for phenylketonuria in the United Kingdom 1964-78. Medical Research Council Steering Committee for the MRC/DHSS Phenylketonuria Register.
Journal: BMJ (1981)

From 1964 to 1968, despite a general policy of routine neonatal screening for phenylketonuria that was usually carried out using the Phenistix nappy test, half to one-quarter of all cases reported to the register had been missed in the screening programme and had not been detected before the age of 4 months. In about two-thirds of the "missed" cases no screening test had been carried out, and in one-third a urine test had been performed but had given a false-negative result. In 1968-9 the screening programme was reorganised according to recommendations made in a Government circular (HM (69) 72), which proposed that a specimen of blood should be obtained by heel prick from all newborn infants between the 6th and 14th day of life and be tested in a central laboratory for the presence of raised blood phenylalanine concentrations. The senior medical officers of the various regions were made responsible for ensuring that all infants were tested. By 1974 only 1 to 2% of surviving infants were not being tested for phenylketonuria in the neonatal period, and only five of the 357 cases born between 1974 and 1978 and notified to the register had been diagnosed after the age of 3 months.
Administration of an Adenosine A2A receptor agonist (ATL-146e) significantly reduces infarct size in a canine model of coronary occlusion and reperfusion David K. Glover, Mirta Ruiz, Laurent M. Riou, Kazuya Takehana, Philip W. Smith, Jayson M. Rieger, Timothy L. Macdonald, Denny D. Watson, Joel Linden, George A. Beller. University of Virginia, Charlottesville, VA
Journal: Journal of the American College of Cardiology (2001)
Actinomycosis presenting as Wegener's granulomatosis
Authors: R. Smith
Journal: JAMA (1978)

A MAN with thoracic actinomycosis had disseminated lesions. Initial biopsy specimens showed a granulomatous vasculitis and absent sulfur granules. Several cultures were negative. The correct diagnosis was not made for a long period, and the clinical and pathologic findings suggested a form of Wegener's granulomatosis. It was not until repeated biopsy specimens and cultures showed the organism that the diagnosis of actinomycosis was made. This case illustrates the importance of proper and persistent microbiologic techniques. <h3>Report of a Case</h3> A 43-year-old man was referred to the hospital because of a six-month history of coughing, weight loss, hemoptysis, coryza, and nosebleeds. At that time, he had a positive PPD tuberculin test, and the chest roentgenogram showed an infiltrate in the right upper lobe and right lower lobe. He also had fluctuant skin masses on the dorsum of the hands bilaterally and on the right thigh. Clinically, these were thought to represent
Evidence for intracellular edema in euvolemic heart failure patients Jonathan Sackner-Bernstein, Catalin Toma, Pilar Haynes, Jack Wang, Chris Nunez, John Thornton, Donald Kotler, Richard N. Pierson, Steven B. Heymsfield. St. Luke's-Roosevelt Hospital Center, New York, NY
Journal: Journal of the American College of Cardiology (2001)
Modeling consciousness
Authors: Frédéric Dandurand, Thomas R. Shultz
Journal: Behavioral and Brain Sciences (2002)

Perruchet &amp; Vinter do not fully resolve issues about the role of consciousness and the unconscious in cognition and learning, and it is doubtful that consciousness has been computationally implemented. The cascade-correlation (CC) connectionist model develops high-order feature detectors as it learns a problem. We describe an extension, knowledge-based cascade-correlation (KBCC), that uses knowledge to learn in a hierarchical fashion.
The USA and its discontents
Authors: None The Lancet Psychiatry
Journal: The Lancet Psychiatry (2020)

In June 2019, The Mental Health for US campaign launched with the goal of putting mental health policies at the forefront of US politics, and making public discussion of mental illness more informed and less stigmatising. Unfortunately, this effort has gained little traction with the two most prominent presidential candidates. For Donald Trump, who seems deeply untroubled by details such as the unrelenting toll of COVID-19, this comes as no surprise. More disappointing is the lack of attention to mental health issues from Joe Biden, who, when speaking about specific mental health topics—addiction, for example—seems stuck in an outdated form of thinking.
Pembrolizumab (PEM) plus granulocyte macrophage colony stimulating factor (GM-CSF) in advanced biliary cancers (ABC): Final outcomes of a phase 2 trial.
Authors: Robin Kate Kelley, Paige M. Bracci, Bridget Keenan, Spencer Behr, Faaiz Ibrahim, Marin Pollak, John Gordan, Andrew H. Ko, Katherine Van Loon, Chloe Evelyn Atreya, Pelin Cinar, Alan P. Venook, Lawrence Fong
Journal: Journal of Clinical Oncology (2022)

444 Background: Immune checkpoint inhibitors (ICI) have limited activity as monotherapy in unselected patients with ABC; the objective response rate (ORR) of PEM was 5.8% in the multicenter phase 2 KEYNOTE-158 trial. GM-CSF modulates immune cells including monocytes and the innate immune response and has demonstrated safety and prolonged survival (OS) in combination with ipilimumab in melanoma. This phase 2 trial was designed to evaluate the efficacy and safety of PEM in combination with GM-CSF in ABC. Methods: Single-center, phase 2 trial with Simon’s 2-stage design and expansion cohort (EC) (NCT02703714). Key eligibility: ABC with progression/intolerance on ≥ 1 standard therapy, no prior ICI, bilirubin ≤1.5xULN. Treatment: PEM 200 mg IV Q21 days plus 2 cycles of GM-CSF 250 µg SC D1-14 Q21 days in cycles 2 and 3 (Stage 1 and EC) or in cycles 1 and 2 (Stage 2). Primary endpoint was objective response rate (ORR) by RECIST 1.1, H 0 5% vs. H 1 20%. Key secondary endpoints were safety, progression-free survival (PFS), OS, PD-L1 expression. Exploratory endpoints included relationship between efficacy outcomes and anatomic subsite, risk factors, and tumor genotype. Results: Overall, 42 patients enrolled between 5/2016-12/2019: n = 9 in Stage 1, n = 18 in Stage 2, and n = 15 in EC. Overall: median age 61; female 67%; intrahepatic (ICC) 67%, extrahepatic (ECC) 26%, gallbladder (GBC) 7%; stage IV 90%; hepatitis B/C virus positive (HBV/HCV+) 24%; microsatellite instability (MSI-H)/stable (MSS)/unknown n = 1/35/6. Immune-related (ir)AE occurred in 69%, grade 3/4 treatment-related (tr)AE in 10%, all-cause serious (S)AE in 36%, and trSAE in 7%. ORR was 12% (95% CI: 4, 26), with median PFS of 63 days (95% CI: 55, 125), PFS at 6 months in 27% (95% CI: 14, 43), and median OS 3of 93 days (95% CI: 243, 573). There was no significant difference in ORR, PFS, or OS by anatomic subsite or tumor PD-L1 expression; HBV/HCV+ showed trends toward higher ORR (30% vs 6%, p = 0.08) and longer median PFS (276 vs 63 days, p = 0.06) and OS (1033 vs 323 days, p = 0.052). Conclusions: The combination of PEM plus GM-CSF was safe and well-tolerated with higher ORR than expected for PEM monotherapy in a predominantly MSS ABC population but did not meet target ORR threshold for efficacy. ORR and median PFS and OS were highest in patients with underlying HBV or HCV infection. Immune profiling of on-treatment biopsies and peripheral blood are ongoing to ascertain influence of both PEM and GM-CSF on circulating and tumor immune microenvironment. Clinical trial information: NCT02703714.
2013 ACCF/AHA Guideline for the Management of Heart Failure: Executive Summary
Authors: Clyde W. Yancy, Mariell Jessup, Biykem Bozkurt, Javed Butler, Donald E. Casey, Mark H. Drazner, Gregg C. Fonarow, Stephen A. Geraci, Tamara Horwich, James L. Januzzi, Maryl R. Johnson, Edward K. Kasper, Wayne C. Levy, Frederick A. Masoudi, Patrick E. McBride, John J.V. McMurray, Judith E. Mitchell, Pamela N. Peterson, Barbara Riegel, Flora Sam, Lynne W. Stevenson, W. H. Wilson Tang, Emily J. Tsai, Bruce L. Wilkoff
Journal: Journal of the American College of Cardiology (2013)